✦ LIBER ✦

P107 Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase

✍ Scribed by S. Jootar

Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 51 KB
Volume: 21
Category: Article
ISSN: 0268-960X
DOI: 10.1016/s0268-960x(07)70185-6

No coin nor oath required. For personal study only.

✦ Synopsis

6/155), high white cell number (13/155) (red cell unit) or low thrombocyte number (14/125) (thrombocyte unit). Summary: Donors with low hemoglobin levels have to be excluded from the blood donation service for 3 months. So, in theory haemoglobin concentration of all total blood units is suitable for preparation the good quality basic units. If we systematically check the quality of the basic units, we can avoid or repair the technical faults of production.

CMPD, Friday 31 August 2007

P107 Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase

📜 SIMILAR VOLUMES

Chromosomal abnormalities in Philadelphi

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

✍ Jorge Medina; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Ma 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract ## BACKGROUND Anecdotal cases of chromosomal abnormalities in Philadelphia chromosome (Ph)‐negative metaphases have been reported in patients with chronic myelogenous leukemia (CML) in the chronic phase during treatment with interferon and, more recently, with imatinib. This phenomenon

Imatinib mesylate therapy improves survi

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase : Comparison with historic data

✍ Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Francis J. Giles; Mary Beth Ri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

## Abstract ## BACKGROUND The International Randomized study of Interferon‐alpha plus cytarabine (IFN‐α plus ara‐C) versus STI571 (imatinib mesylate) [IRIS trial] in patients with newly diagnosed Philadelphia chromosome (Ph)‐positive, chronic‐phase chronic myelogenous leukemia (CML) has not shown

Sudden blast crisis in patients with Phi

Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy

✍ Giuliana Alimena; Massimo Breccia; Roberto Latagliata; Ida Carmosino; Eleonora R 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

The prognosis for patients with chronic

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

✍ Michael W. N. Deininger; Jorge Cortes; Ron Paquette; Byung Park; Andreas Hochhau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 380 KB

## Abstract ## BACKGROUND. Clonal cytogenetic abnormalities (CCA) were detected in Philadelphia chromosome (Ph)‐negative cells in some patients with chronic myeloid leukemia (CML) who attained a cytogenetic response to imatinib mesylate. In some patients, CCA/Ph‐negative status was associated with

Prediction of initial cytogenetic respon

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

✍ Mark W. Drummond; Tessa L. Holyoake 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

Prediction of initial cytogenetic respon

✍ Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Ke 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## Abstract ## BACKGROUND Obtaining a major (Philadelphia chromosome [Ph] of < 35%) or a complete cytogenetic response (Ph of 0%) has been associated with excellent long‐term survival. Cytogenetic response may continue to improve with therapy. Because early allogeneic stem cell transplantation (SC